National Alzheimer's Project Act

BrainCheck Expands First End-to-End Solution for Cognitive Care

Retrieved on: 
Tuesday, October 24, 2023
Summit Health, Alzheimer's disease, University of Washington School of Medicine, National Alzheimer's Project Act, Moca, Trial of the century, AD, Montreal Cognitive Assessment, Health information management, Medicare, Breast Cancer Awareness Month, Data, Deficit spending, D.O, Health, Research, Clinical trial, Dementia, Severity, Tablet, University, MSE, EHR, Patient, Computerize, Montreal, Cholesterol, Medical imaging, Medical device, MD, Index

AUSTIN, Texas, Oct. 24, 2023 /PRNewswire/ -- BrainCheck, Inc. launched the next generation of its comprehensive platform and unveiled its latest innovation, BrainCheck® Screen™, at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, Massachusetts from October 24-27, ahead of National Alzheimer's Awareness Month. New research supporting BrainCheck's comprehensive digital cognitive assessment tool will also be presented at the meeting.

Key Points: 
  • "More than six million Americans have Alzheimer's disease (AD), the most common type of dementia, but unfortunately many remain undiagnosed,i" said Kim Rodriguez, CEO of BrainCheck.
  • "Early diagnosis will help close this gap, and our platform empowers providers to easily access information on patients' cognitive health by offering a unique solution that includes screening, assessment, care planning, and monitoring.
  • The latest version brings cognitive care to the next level, expanding access to our technology from any device or location, in-clinic or remote.
  • The next generation of the BrainCheck platform allows digital cognitive testing on any internet-connected device – including phones, tablets and browsers – regardless of the patient or clinician's location.

Stanford Pathology Chair and Expert in Alzheimer's and Parkinson's Disease Joins Enable Medicine's Scientific Advisory Board to Advance Digital Pathology Capabilities

Retrieved on: 
Wednesday, June 14, 2023
American Association of Neuropathologists, National Science Advisory Board for Biosecurity, Drug development, University, Alzheimer's disease, Stanford University, Marie Cassidy, NIA, United States Air Force Scientific Advisory Board, Intelligence, Research, Stanford University Medical Center, Advisory board, Parkinson's disease, Neuropathology, University of Washington Department of Global Health, NINDS, NIH, Medicine, National Alzheimer's Project Act, Medical device, Pathology

MENLO PARK, Calif., June 14, 2023 /PRNewswire/ -- Enable Medicine announced today that Dr. Thomas Montine has joined its Scientific Advisory Board .

Key Points: 
  • MENLO PARK, Calif., June 14, 2023 /PRNewswire/ -- Enable Medicine announced today that Dr. Thomas Montine has joined its Scientific Advisory Board .
  • Dr. Montine joins eight other leaders in the fields of artificial intelligence, drug development, and oncology on the Advisory Board.
  • Dr. Montine is the Chair of the Department of Pathology at Stanford University where he is the Stanford Medicine Endowed Professor in Pathology and is on the Board of Directors of Stanford Health Care.
  • Dr. Montine is among the top recipients of NIH funding for all Department of Pathology faculty in the United States.

For people living with dementia, support changes everything

Retrieved on: 
Tuesday, January 3, 2023
Dementia, Quality of life, Alzheimer Society of Canada, Education, Disease, Arogyavani (104 Health Helpline Number), Knowledge, Alzheimer's disease, Diagnosis, Society, CIHI, National Alzheimer's Project Act, Caregiver, Research, ALS Awareness Month, Residential care

Alzheimer Society of Canada hopes to connect people living with dementia to support, knowledge and community

Key Points: 
  • Alzheimer Society of Canada hopes to connect people living with dementia to support, knowledge and community
    TORONTO, Jan. 3, 2023 /CNW/ - A diagnosis of dementia is not easy.
  • To get connected to your local Alzheimer Society for support, visit www.alzheimer.ca/FirstLink
    The Alzheimer Society is Canada's leading nationwide health charity for people living with Alzheimer's disease and other dementias.
  • Data from the CIHI has shown that:
    45% of care partners providing care to people living with dementia exhibit symptoms of distress.
  • Alzheimer Societies across Canada provide caregivers and families with information, education and resources to help them support the person in their care who is living with dementia.

The Rockefeller Foundation's Public Charity Expands Project ACT to Provide At-Risk Communities Nationwide with Free At-Home Covid-19 Tests

Retrieved on: 
Wednesday, June 29, 2022
ACT, National Alzheimer's Project Act, Science, Rockefeller Foundation, Michigan Department of Licensing and Regulatory Affairs, Kansas Department of Health and Environment, Kansas Department of Agriculture, COVID-19, Death, North Carolina Department of Health and Human Services, Program, Eligibility, Public health, Textbook, Michigander, South Carolina Department of Health and Environmental Control, New Mexico Department of Health, Risk, Partnership, Technology, Project, Environment, Health, Human services, NEW, RFCC, MD, State, Hispanic and Latino Americans, CDC, Amazon (company), Michigan Department of Health and Human Services, Pharmaceutical industry

NEW YORK, June 29, 2022 /PRNewswire/ -- The Rockefeller Foundation, through its public charity RF Catalytic Capital (RFCC), announced the nationwide expansion of Project Access Covid Tests (Project ACT) to provide free at-home Covid-19 tests directly to at-risk communities across the United States. After working with health departments in six states to deliver an initial one million tests, RFCC is opening up the program to all U.S. states and territories. Already, health departments in five states – Maine, New Mexico, Kansas, Michigan, and North Carolina – have signed up and committed funding to secure 1.2 million tests. Enrollment for health departments is open through August 31, 2022, with tests to be distributed through the end of February 2023.

Key Points: 
  • Enrollment for health departments is open through August 31, 2022, with tests to be distributed through the end of February 2023.
  • "Project ACT has successfully demonstrated this type of collaborative effort in action.
  • The Rockefeller Foundation provided the initial $7.45 million in January to pilot Project ACT.
  • "Partnering with Project ACT helps us improve access to testing, especially in our communities with historic lack of access to health care."

Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal

Retrieved on: 
Wednesday, June 22, 2022
Plasma protein binding, Cognition, Alzheimer's Association, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Medicines and Healthcare products Regulatory Agency, Therapy, BLA, Marketing, QOL, Health, Quality of life, Quality-adjusted life year, ICER, Clinical trial, QALY, Data, National Alzheimer's Project Act, Alzheimer's disease, CEO, Brain, Amyloid beta, Clarity, Institute for Clinical and Economic Review, FDA, Drug development, Decision-making, Society, PMDA, ADNI, Institute, Life expectancy, Medication, SOC, Trust, Biologics license application, Pharmaceuticals and Medical Devices Agency, Friends, Association, Uncertainty, Senior, Safety, NACC, Trial of the century, Family, Food, AD, VBP, Pharmaceutical industry, Medical device, Health insurance, Patient, Neurology, Disease, Eisai

To that end, Eisai would like to provide a common foundation for stakeholders' discourse regarding the potential clinical and socioeconomic value of lecanemab from the societal perspective, not to assign a price for lecanemab at this time.

Key Points: 
  • To that end, Eisai would like to provide a common foundation for stakeholders' discourse regarding the potential clinical and socioeconomic value of lecanemab from the societal perspective, not to assign a price for lecanemab at this time.
  • It also estimated the potential economic value of lecanemab+SoC over a broad range of willingness-to-pay thresholds from $50,000 to $200,000 per QALY gained as recommended by the Institute for Clinical and Economic Review (ICER)*****.
  • The potential annual value-based price (VBP) of lecanemab was estimated at $9,249 to $35,605 (Societal perspective: $10,400 to $38,053) based on this early economic assessment.
  • The Phase 3 lecanemab Clarity AD data will soon be available to inform the model inputs and refine the findings.

Alzheimer Society Launches Campaign with a Call for Support for People Diagnosed with Dementia

Retrieved on: 
Wednesday, January 5, 2022
Knowledge, Well, Alzheimer Society of Canada, Caregiver, Disease, Indigenous Disability Awareness Month, Alzheimer's disease, Education, URL, Dementia, Community, Alzheimer Society of Ontario, Society, Uncertainty, Community Research and Development Information Service, Quality of life, Awareness, National Alzheimer's Project Act, Diagnosis, Online gambling, Residential care, Health insurance, Advocacy, Research

The Alzheimer Society is the first place to turn and First Link is the connection to support, care, knowledge, expertise, and referrals.

Key Points: 
  • The Alzheimer Society is the first place to turn and First Link is the connection to support, care, knowledge, expertise, and referrals.
  • First Link is the Alzheimer Society program offering approved services and information to those living with Alzheimer's or other dementias, and caregivers.
  • The Alzheimer Society Research Program is Canada's leading funder of research into better understanding the causes of dementia, improving treatment and care, and towards finding cures.
  • Alzheimer Societies across Canada provide programs and support services for people with all forms of dementia, including Alzheimer's disease, and their caregivers.

iSpecimen Expands Supplier Network of Human Biospecimens to Help Advance Research in Neurological Disorders

Retrieved on: 
Thursday, December 2, 2021
Patient, Research, Security (finance), CEO, Review, Securities Act of 1933, Cell, Risk, Forward-looking statement, Company, ALS, Hospital, Smell, UN, MD, Cerebrospinal fluid, U.S. Securities and Exchange Commission, Alzheimer's disease, Lists of diseases, COVID-19, Office of Biorepositories and Biospecimen Research, Lyme Disease Awareness Month, Securities Exchange Act of 1934, National Alzheimer's Project Act, Myalgia, Organization, Amyotrophic lateral sclerosis, Parkinson's disease, Headache, The Company, Doctor of Philosophy, Stroke, CNS, Neurological disorder, Fluid mechanics, Pharmaceutical industry

In the past 10 months, iSpecimen has added more than a dozen sample providers to its network of suppliers that provide access to banked or custom collections of biospecimens such as cerebrospinal fluid, other biofluids, or cells to help advance CNS research.

Key Points: 
  • In the past 10 months, iSpecimen has added more than a dozen sample providers to its network of suppliers that provide access to banked or custom collections of biospecimens such as cerebrospinal fluid, other biofluids, or cells to help advance CNS research.
  • Neurological disorders include amyotrophic lateral sclerosis (or ALS), Alzheimer's disease, Parkinson's disease, and stroke.
  • Also, some COVID-19 patients report neurological symptoms such as muscle aches, headaches, and loss of taste or smell.
  • These are among a wide range of human tissue , biofluids , and hematopoietic stem and immune cells to which iSpecimen provides access through the iSpecimen Marketplace .

Alzheimer's Association Honors and Empowers Caregivers During National Family Caregivers Month and National Alzheimer's Disease Awareness Month

Retrieved on: 
Monday, November 1, 2021
Spend, Woman, Helpline, Dementia, Disease, Hispanic and Latino Americans, History, Advertising, Prescription, Alzheimer's Association, Ad Council, Marketing, Trial of the century, Multimedia, Council, Radio, Research, Diagnosis, National Environmental Engineering Research Institute, Association, Holiday, Income, Investment, Friends, Content, PSAS, United States Census, Industry, Roundarm trial matches, Caregiver, Long, WPP, Television, Risk, Growth, Awareness, Cooking, Population, Technology, LinkedIn, Creativity, Mind share, YouTube, Empathy, Time, Adult, Cognition, Bias, National Alzheimer's Project Act, Health status of White Americans, Digital, Lyme Disease Awareness Month, Residential care, Online shopping, Public relations, Sales

CHICAGO, Nov. 1, 2021 /PRNewswire/ --During National Alzheimer's Disease Awareness Month and National Family Caregivers Month in November, the Alzheimer's Association is teaming up with the Ad Council to launch a new national communications campaign "Hopeful Together."

Key Points: 
  • CHICAGO, Nov. 1, 2021 /PRNewswire/ --During National Alzheimer's Disease Awareness Month and National Family Caregivers Month in November, the Alzheimer's Association is teaming up with the Ad Council to launch a new national communications campaign "Hopeful Together."
  • According the survey, more than 4 in 5 Americans (83%) say they want family members to share concerns if signs appear.
  • During National Family Caregivers Month in November, the Alzheimer's Association is also encouraging all Americans to support Alzheimer's and dementia caregivers.
  • The Alzheimer's Association offers these suggestions:
    Learn:Educate yourself about Alzheimer's disease its symptoms, its progression and the common challenges facing caregivers.